Author

Rolf Marschalek

Professor f

Biography

Rolf Marschalek is a well-known researcher working in Department of Biochemistry, Chemistry & Pharmacy Marschalek, Goethe-University of Frankfurt and has extended valuable service for many years and has been a recipient of many awards and grants.  
Title
Cited by
Year
Anti–platelet factor 4 antibodies causing VITT do not cross-react with SARS-CoV-2 spike protein
A Greinacher, K Selleng, J Mayerle, R Palankar, J Wesche, S Reiche, ...Blood, The Journal of the American Society of Hematology 138 (14), 1269-1277, 2021202
98
2021
Vaccine-induced COVID-19 mimicry syndrome
E Kowarz, L Krutzke, M Külp, P Streb, P Larghero, J Reis, S Bracharz, ...Elife 11, 2022202
93
2022
Limited neutralisation of the SARS-CoV-2 Omicron subvariants BA. 1 and BA. 2 by convalescent and vaccine serum and monoclonal antibodies
A Wilhelm, M Widera, K Grikscheit, T Toptan, B Schenk, C Pallas, ...EBioMedicine 82, 2022202
70
2022
Generation of a sleeping beauty transposon-based cellular system for rapid and sensitive screening for compounds and cellular factors limiting SARS-CoV-2 replication
M Widera, A Wilhelm, T Toptan, JM Raffel, E Kowarz, F Roesmann, ...Frontiers in microbiology 12, 701198, 2021202
23
2021
Outcomes for Australian children with relapsed/refractory acute lymphoblastic leukaemia treated with blinatumomab
R Sutton, LD Pozza, SL Khaw, C Fraser, T Revesz, J Chamberlain, ...Pediatric blood & cancer 68 (5), e28922, 2021202
16
2021
Epigenetic regulator genes direct lineage switching in MLL/AF4 leukemia
R Tirtakusuma, K Szoltysek, P Milne, VV Grinev, A Ptasinska, PS Chin, ...Blood, The Journal of the American Society of Hematology 140 (17), 1875-1890, 2022202
12
2022
Image-based annotation of chemogenomic libraries for phenotypic screening
A Tjaden, A Chaikuad, E Kowarz, R Marschalek, S Knapp, M Schröder, ...Molecules 27 (4), 1439, 2022202
10
2022
In vivo inducible reverse genetics in patients’ tumors to identify individual therapeutic targets
M Carlet, K Völse, J Vergalli, M Becker, T Herold, A Arner, D Senft, ...Nature communications 12 (1), 5655, 2021202
9
2021
Lineage switch to acute myeloid leukemia during induction chemotherapy for early T-cell precursor acute lymphoblastic leukemia with the translocation t (6; 11)(q27; q23)/KMT2A …
Z Permikin, A Popov, T Verzhbitskaya, T Riger, O Plekhanova, ...Leukemia research 112, 10678, 2022202
5
2022
The KMT2A recombinome of acute leukemias in 2023
C Meyer, P Larghero, B Almeida Lopes, T Burmeister, D Gröger, R Sutton, ...Leukemia 37 (), 988-100, 2023202
5
2023
The role of reciprocal fusions in MLL-r acute leukemia: studying the chromosomal translocation t(4;11)
The role of reciprocal fusions in MLL-r acute leukemia: studying the chromosomal translocation t(;11)A Wilhelm, R MarschalekOncogene 0 (2), 6093-6102, 2021202
4
2021
Novel Diagnostic and Therapeutic Options for KMT2A-Rearranged Acute Leukemias
BA Lopes, CP Poubel, CE Teixeira, A Caye-Eude, H Cavé, C Meyer, ...Frontiers in Pharmacology 1, 749472, 2022202
3
2022
Detection and Quantification of SARS-CoV-2 by Real-Time RT-PCRReverse transcription-polymerase chain reaction (RT-PCR) Assay
Detection and Quantification of SARS-CoV- by Real-Time RT-PCRReverse transcription-polymerase chain reaction (RT-PCR) AssayA Wilhelm, C Pallas, R Marschalek, M WideraSARS-CoV-: Methods and Protocols, 75-98, 0
2
2022
Therapy-related acute myeloid leukemia with KMT2A-SNX9 gene fusion associated with a hyperdiploid karyotype after hemophagocytic lymphohistiocytosis
Therapy-related acute myeloid leukemia with KMTA-SNX9 gene fusion associated with a hyperdiploid karyotype after hemophagocytic lymphohistiocytosisI Sardou-Cezar, BA Lopes, FG Andrade, TCC Fonseca, ...Cancer Genetics 56, 86-90, 010
2
2021
The differential role of the lipid raft-associated protein flotillin 2 for progression of myeloid leukemia
The differential role of the lipid raft-associated protein flotillin for progression of myeloid leukemiaR Kumar, RS Pereira, J Niemann, AI Azimpour, C Zanetti, C Karantanou, ...Blood Advances 6 (1), 3611-364, 0
2
2022
The immune checkpoint ICOSLG is a relapse-predicting biomarker and therapeutic target in infant t (4; 11) acute lymphoblastic leukemia
M Külp, AL Siemund, P Larghero, A Dietz, J Alten, G Cario, C Eckert, ...Iscience 5 (7), 0
2
2022
HIV-1 infection of long-lived hematopoietic precursors in vitro and in vivo
S Renelt, P Schult-Dietrich, HM Baldauf, S Stein, G Kann, M Bickel, ...Cells 11 (19), 968, 0
2
2022
The ENL YEATS epigenetic reader domain critically links MLL-ENL to leukemic stem cell frequency in t (11; 19) Leukemia
H Hu, N Saha, Y Yang, E Ahmad, L Lachowski, U Shrestha, V Premkumar, ...Leukemia 37 (1), 190-01, 030
2
2023
KMT2A-MLLT1 and the Novel SEC16A-KMT2A in a Cryptic 3-Way Translocation t (9; 11; 19) Present in an Infant With Acute Lymphoblastic Leukemia
KMT2A-MLLT and the Novel SEC6A-KMT2A in a Cryptic 3-Way Translocation t (9; ; 9) Present in an Infant With Acute Lymphoblastic LeukemiaRRC de Matos, GM Ferreira, C Meyer, R Marschalek, P Larghero, ...Journal of Pediatric Hematology/Oncology 44 (3), e79-e722, 2022202
1
2022
Article The immune checkpoint ICOSLG is a relapse-pre-dicting biomarker and therapeutic target in infant t (4; 11) acute lymphoblastic leukemia
Article The immune checkpoint ICOSLG is a relapse-pre-dicting biomarker and therapeutic target in infant t (4; ) acute lymphoblastic leukemiaM Kulp, AL Siemund, P Larghero, A Dietz, J Alten, G Cario, C Eckert, ...ISCIENCE 25 (7), 2022202
1
2022

Referred From: https://scholar.google.de/citations?user=UzPAjtUAAAAJ&hl=de

Cited by
Citations 10676
h-index 53
i10-index 169
Recommended Journals
Open Access Journals